Technology

Market dynamics boost the need and urgency for more sophisticated benchmarking strategies.

EVERSANA’s chief digital officer discusses recent developments in the pharma industry that are impacting its relationship with patients and new technology.

Heather Gervais, CEO of Osso VR, discusses how technological advancements in VR are solving problems for pharmaceutical sales reps.

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

The CEO discusses his company’s platform that helps reformulate oral solid dose medications to liquid forms.

The benefits for brand teams in bolstering their rapid-response capability.

The TileDB CEO discusses how the life sciences can overcome these limitations.

The energy component—and cost—associated with artificial intelligence should not be overlooked in all the excitement.

Guidance marks the regulatory body’s first on artificial intelligence applications in drug and biological product development.

A Q&A with Harvard’s Laura Wegner, serial entrepreneur and Rhodes Scholar-elect.

In the third part of this roundtable discussion, experts discuss the issues with data that AI must overcome.

The Upscript Health CEO discusses trends in telehealth for the coming year.

How alternative direct-to-consumer models are changing the landscape for patient access.

The swell of AI-powered digital platforms puts future decision-making under the spotlight.

A look at the promise and opportunities from this new and advanced type of AI in transforming commercial planning and execution for life sciences companies.

In the second part of this roundtable discussion, experts discuss how the industry is handling AI in the marketing space.

AI provides opportunities to bring people together—not replace them.

Because the AI space is changing rapidly, it’s essential that companies are budgeting correctly and using their investments strategically.

In this first part of this roundtable discussion, experts discuss the current perception of AI and how this is impacting adoption.

EVERSANA’s chief digital officer discusses the current relationship between pharma and AI.

As skepticism surrounding AI fades, pharma industry execs are ready to embrace the technology.

Ann Beliën, PhD, founder and CEO of Rejuvenate Biomed, discusses how AI is being used to find new ways to treat age-related conditions.

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.

Pleio’s chief experience officer discusses why these platforms are being embraced by the industry.

Pharma looks to take advantage of expanded access programs across Asia-Pacific region.

The alliance’s president discusses the current state of data sharing, security concerns, and the adoption AI.

Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.

Slope’s CEO and co-founder discusses technological advances that are solving problems with data collection and sorting from clinical trials.

Practical ways product teams can leverage the benefits of generative artificial intelligence as a strategic advantage in pharmaceutical and life sciences commercialization.